# Junta clínica — PT-pseudo_b6db06db35d7 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b6db06db35d7",
  "pid": "PT-pseudo_b6db06db35d7",
  "task": 1,
  "psa": 5.2,
  "age": 57,
  "months": 1,
  "pirads": "5",
  "psad": 0.11,
  "psav": 1.38,
  "psap": 3.2,
  "vol": 47.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8199149,
  "medhx": "Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "tamsulosin",
  "notes": "PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.",
  "pmhx": [
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "79 kg",
    "height": "182 cm",
    "bmi": "23.8",
    "bp": "119/89 mmHg",
    "hr": "73 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result."
    },
    {
      "s": "History",
      "t": "A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Widowed",
  "living": "Lives alone",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Pulmonary function test — known COPD follow-up",
    "Cardiology — annual review (stable, autumn 2024)"
  ],
  "alcohol": "10 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 11/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b6db06db35d7
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 5.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.38 ng/mL/yr
  - Prior PSA: 3.2 ng/mL
  - Prostate volume: 47.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8199149 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 5.2 ng/mL. PI-RADS 5. PSAD 0.11. Prostate volume 47 mL. csPCa 0.82.

Vitals: weight 79 kg, height 182 cm, BMI 23.8, BP 119/89 mmHg, HR 73 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a recent PSA climb to 5.2 ng/mL alongside a newly identified PI-RADS 5 MRI finding and a previously Positive prior biopsy result.

History: A 57-year-old non-smoker who lives independently, this widowed semi-retired musician carries a background of benign prostatic hyperplasia currently treated with tamsulosin. His initial urological workup began in early 2023 when a PSA reading of 2.3 ng/mL was noted, ultimately yielding a Positive prior biopsy. He experiences moderate lower urinary tract complaints, characterized by nocturia occurring twice each night and a diminished stream, yielding an IPSS of 11. Past medical history includes knee osteoarthritis and stable chronic obstructive pulmonary disease, the latter prompting a pulmonary function assessment earlier this month. He walks 45 minutes daily, limits alcohol to roughly 10 units per week, and enjoyed a stable cardiology check in autumn 2024. He explicitly denies bone discomfort, haematuria, or unaccounted weight reduction, citing only the 60-minute train journey to the clinic as a notable daily logistical hurdle.

Physical examination: Per rectum: DRE confirms a normal examination with a symmetrically enlarged prostate, smooth and firm consistency, and absent nodules or asymmetry. General assessment shows stable vitals (BP 119/89 mmHg, HR 73 bpm) with no abdominal masses or lymphadenopathy. Nutritional status appears adequate, and independent ambulation is noted, accompanied by a mild antalgic gait attributable to established osteoarthritis.

Patient info: musician (semi-retired); Widowed; Lives alone.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 10 units / week; exercise Walking 45 min/day; IPSS score: 11/35 (moderate LUTS).

Recent other appointments: Pulmonary function test — known COPD follow-up; Cardiology — annual review (stable, autumn 2024).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.57
  uncertainty  +/- 0.10 epistemic (95% band 0.36-0.77); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.03: PI-RADS 5, PSA 4.53, PSAD 0.12, age 50, DRE Normal -> BIOPSY (clear). He wrote: "young patient with pirads5= high probability of significant prostate cancer and only one prev biopsy, increasing PSA. indicated with one more confirmatory biopsy to excl…"
  2. distance 1.49: PI-RADS 5, PSA 12.0, PSAD 0.28, age 61, DRE Normal -> DEFER (borderline). He wrote: "Young patient with elevated PSA (>10), elevated PSA density, PIRADS5 and ISUP GG2 disease -> low threshold for recommending curative treatment. IF patient does not want…"
  3. distance 1.71: PI-RADS 5, PSA 8.7, PSAD 0.4, age 54, DRE Normal -> BIOPSY (uncertain). He wrote: "Young patient with high risk disease, should be recommended curative treatment. Biopsy report congruent with MRI, probably caught the index cancer at diagnosis. Highrisk…"

PRECEDENT: BIOPSY (weighted vote 0.70 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. It also states that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings and the PSA density threshold. The panel variables alone do not settle the decision when the guideline suggests exclusion based on stable MRI and low PSA-D.

WHAT WE STILL NEED
The prior-biopsy status is known: Positive. The guideline requires knowing if a repeat biopsy is mandated based on MRI findings or PSA density. The PSA density is known: 0.11 ng/mL². The prior biopsy grade and biopsy dates are needed to determine if a repeat biopsy is required according to the guideline.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on determining the required follow-up based on the prior biopsy grade and surveillance status, as the guideline suggests the MRI stability and PSA density might exclude a repeat biopsy.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What was the prior biopsy grade (Gleason/ISUP), the number and dates of biopsy sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior biopsy?
  Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Facility: Spaarne Gasthuis, Haarlem | Date: 08 Jan 2025
What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
Lesion size: 12 x 9 mm in the right mid peripheral zone. Extraprostatic extension: not specified. Comparison against an earlier study: new.

psa_trend
What is the serial PSA value trend (rising, flat, or falling)?
Serial PSA value trend: rising, from 0.6 ng/mL on Jan 2023 to 3.3 ng/mL on Jan 2024 to 5.2 ng/mL on Jan 2025.

previous_notes
What was the prior biopsy grade (Gleason/ISUP), the number and dates of biopsy sessions, and surveillance protocol status?
Prior biopsy grade: Gleason 3+3. Number and dates of biopsy sessions: one session in July 2023. Surveillance protocol status: not recorded.

laboratory_results
What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?
Free-PSA fraction: 22% on 21 Dec 2024. Renal function (Creatinine): 103 umol/L, eGFR: >60 mL/min/1.73m2. Haemoglobin: 14.5 g/dL.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided the necessary information regarding the prior biopsy grade and surveillance status.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion identified in the right mid peripheral zone.
Rising PSA trend from 3.3 ng/mL to 5.2 ng/mL.

Findings that argue AGAINST sampling this patient now:
Prior biopsy grade was Gleason 3+3.
Patient is not currently on a surveillance protocol with a confirmatory biopsy due.

WHERE THIS LEANS
The findings suggest a high-risk scenario based on the PI-RADS 5 and rising PSA, but the prior biopsy grade is known.
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 5.20 ng/mL over 3 points spanning 24 months; velocity +2.30 ng/mL per year; doubling time about 8 months.
PROJECTION at 6 months: 6.2 ng/mL, conformal 95% band 1.8-21.7.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.10 epistemic (95% band 0.43-0.83), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.57  ('discuss' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.63  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.70  (k=3 precedents)

  documented prior grade in the opened documents: GG 1 ("Gleason 3+3")

RULE THAT FIRED: documented prior grade GG 1 (Gleason 3+3) — carried by documented grade.
PANEL ANSWER: BIOPSY. A documented GG 1 in a man under surveillance is what a confirmatory biopsy is for: the reading urologist re-sampled 3 of the 4 labelled men with a recorded GG 1.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have answered both moderator questions. The `previous_notes` retrieved the prior biopsy grade as Gleason 3+3 and confirmed the surveillance protocol status as "not recorded."

ALIGNMENT WITH THE PANEL
The retrieved finding, the prior biopsy grade of Gleason 3+3, aligns with the PANEL-PROTOCOL's decision to recommend BIOPSY, as this documented grade was the rule that fired.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior biopsy? Answered by the `previous_notes`: Gleason 3+3.
Q2. Is the patient currently on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: not recorded.

WHAT CARRIES WEIGHT, AND WHY
The prior biopsy grade (Gleason 3+3) is the most critical variable because the PANEL-PROTOCOL explicitly states this documented grade is the rule that fired for the decision. The surveillance status is also crucial as it dictates the necessity of the confirmatory biopsy.

MY SUGGESTION TO THE CHAIR
The record is in a state to be decided because the necessary information regarding the prior biopsy grade was retrieved. The panel protocol's answer rests directly on the retrieved finding of Gleason 3+3. Therefore, the decision should proceed with the recommendation of biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

A confirmatory biopsy is indicated because the prior biopsy yielded a low-grade Gleason 3+3, and the patient is not currently on a surveillance protocol. This decision is driven by the documented prior grade (Gleason 3+3) and the rising PSA trend from 3.3 ng/mL to 5.2 ng/mL. The evidence converged on the need for re-sampling based on the established protocol for this specific prior diagnosis.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
